Abridge aligns with Eli Lilly and Nvidia to push an AI “scribe” into clinical conversations

Abridge, a company known for AI that helps generate clinical notes, said it is working with Nvidia to build a foundation model designed for clinical conversations, and it announced a strategic investment from drugmaker Eli Lilly. The announcements were made during a keynote described in a report carried by Yahoo Finance.

In its description of the plan, Abridge framed the work as an effort to move beyond basic transcription into a model that can handle the context and content of patient-clinician conversations, a step that could make documentation more useful during care and review after the visit.

Abridge’s approach centers on an “AI scribe” concept, which generally refers to software that assists clinicians by turning recorded or observed interactions into draft documentation. The company’s stated goal, as described in the report, is to expand that capability by using a larger, more general “foundation model” that can be adapted to specific clinical conversation tasks.

Eli Lilly’s involvement was characterized in the report as a strategic investment rather than a reported commercial contract. While that indicates interest from a major healthcare company, the details of the investment size, terms, and any future partnership scope were not provided in the material available for this write-up.

The Nvidia collaboration was described at a high level as work to build the foundation model for clinical conversations. Nvidia is best known for supplying accelerated computing platforms used for training and running advanced AI systems, though the specific model architecture, datasets, and deployment environment were not disclosed in the cited report.

For Lilly, an AI investment tied to clinical documentation can be interpreted as part of a broader healthcare technology shift, where life sciences companies look to improve how real-world clinical information is captured and standardized. For Abridge and Nvidia, the focus is on increasing the usefulness and sophistication of clinical AI outputs, where accuracy and workflow fit are central to adoption.

A caveat is that the report does not provide granular information on model performance, timeline, regulatory plans, privacy or security safeguards, or whether the foundation model will be used internally, offered to healthcare systems, or delivered through a specific product offering.

What to watch next is whether Abridge and its partners will outline measurable outcomes, such as documentation quality improvements, clinician satisfaction, or integration plans with electronic health record workflows. Additional disclosure on the investment and any joint go-to-market plans would also clarify how much of Lilly’s participation is tied to product deployment versus strategic support.